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Abstract
We have previously described a simple yet effective liposome-based therapeutic vaccine, DOTAP/
E7, which contains only two molecules, the cationic lipid DOTAP and a peptide antigen derived
from the E7 oncoprotein of human papillomavirus (HPV) type 16. In the current report, we have
improved the vaccine formulation by incorporation of E7-lipopeptide instead of the water-soluble
native E7 peptide into the DOTAP liposome. The lipopeptide consists of an N-terminal α- or ∊-
palmitoyl lysine connected to the E7 peptide via a dipeptide Ser-Ser linker. The DOTAP/E7-
lipopeptide vaccine exhibited an enhanced functional antigen-specific CD8+ T lymphocyte response
in vivo compared to the previous DOTAP/E7 formulation. More importantly, the cytotoxic T cells
induced by the DOTAP/E7-lipopeptide vaccine could efficiently eliminate an existing HPV positive
TC-1 tumor. The antitumor activity of lipopeptide formulated in DOTAP liposome was more than
twice as potent as that of native E7, likely owing to the increased peptide entrapment efficiency in
the liposomal complex. Our results also showed that it is essential to have the dipeptide spacer
sequence between E7 peptide and the attached fatty acid to achieve a full immune response. Overall,
the improved DOTAP/E7-lipopeptide vaccine described herein showed a significantly enhanced
therapeutic effect for the treatment of a cervical cancer model.
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Introduction
Liposomes have been extensively used for delivering small molecular weight drugs,1 plasmid
DNA,2 oligonucleotides,3 proteins,4,5 and peptides.6 From a safety standpoint, a liposomal
vehicle as a nonviral vaccine carrier has been regarded as a preferable strategy compared to
traditional immunizations using live attenuated vaccines or viral vectors such as vaccinia or
influenza virus.7,8 Recent studies from our group have led to the development of a simple yet
effective peptide-based liposomal vaccine, DOTAP/E7 complex, which consists of only two
molecules, the cationic lipid DOTAP and a peptide antigen which is derived from E7
oncoprotein of human papillomavirus (HPV) type 16. The DOTAP/E7 formulation was able
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to induce both preventative and therapeutic antitumor effects against HPV positive TC-1 tumor
in a mouse model. Our results have demonstrated for the first time that the cationic liposome
alone not only plays the role of a carrier to deliver the peptide antigen to the antigen presenting
cells (APC) but also serves as a potent vaccine adjuvant to stimulate immune responses and
initiate DC-T cell interactions.9,10
There has been considerable interest in developing lipopeptide formulations for both humoral
and cellular immune response. This is in contrast to the native synthetic peptides which are
poorly immunogenic. Peptides linked with monoor multipalmitic acid are capable of producing
an antigen-specific cytotoxic T lymphocyte response against infectious diseases such as HIV,
11,12 HBV,13 and malaria,14 and several clinical trials are investigating this effect.15,16
However, lipopeptides have limited solubility and require a means for solubilization. Since
liposome is a good carrier for lipophilic drugs, we investigated the possibility of formulating
a lipopeptide antigen in the DOTAP liposomes. Our results showed significantly improved
immunogenic activity of the lipopeptide as compared to the original E7 peptide. We have also
evaluated the antitumor activity of the E7-lipopeptide in DOTAP liposome in the TC-1 cervical
cancer model in mice.
Materials and Methods
Lipids, Reagents, and Murine Tumor Cell Lines.
DOTAP was purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). Murine TC-1 cells
were kindly provided by Dr. T. C. Wu at Johns Hopkins University (Baltimore, MD). TC-1
cells are C57BL/6 mouse lung epithelial cells transformed with HPV 16 E6 and E7 oncogenes
and the activated H-ras. RMA-S, a mouse lymphoma cell line, was kindly provided by Dr. J.
Frelinger at the University of North Carolina at Chapel Hill. Both H-2b murine tumor cell lines
were maintained in RPMI-1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10%
fetal bovine serum, 100 units/mL of penicillin, and 100 μg/mL of streptomycin (Invitrogen).
Peptide Synthesis
Peptides and lipopeptides (Table 1) containing an H-2Db-restricted CTL epitope (amino acid
49–57, RAHYNIVTF) derived from HPV 16 E7 protein were synthesized and purified at the
Molecular Medicine Institute Peptide Synthesis Facility at the University of Pittsburgh. Briefly,
lipopeptides used in this study were generated by elongating the N-terminal of E7 peptide with
a linker peptide Lys-Ser-Ser (KSS), and a palmitic acid was then attached to the α-or ∊-amino
group of the Lys residue. An unlipidated version of KSS-elongated E7 peptide (abbreviated
KSS-E7) or a palmitoylated E7 peptide (fatty acid attached to N-terminal Arg residue without
a spacer sequence; abbreviated PA-E7) was used as control.
Preparation and Characterization of DOTAP/Lipopeptides
Cell culture grade water (Cambrex, Walkersville, MD) was used in all liposome preparations.
Lipopeptide was mixed with DOTAP in CHCl3/MeOH (1:1 mixture) followed by evaporation
under a steady stream of dry nitrogen gas. Traces of organic solvent were removed by vacuum
desiccation overnight. Lipopeptide/lipid films were hydrated by adding water and incubated
at room temperature for 12 h. The suspensions were sonicated in a bath type sonicator for 10
min followed by extrusion (Hamilton Co., Reno, NV) through 400, 200, and 100 nm
polycarbonate membrane (Nuclepore, Pleasanton, CA) and were stored at 4 °C before use. For
preparation of DOTAP/E7 or DOTAP/KSS-E7, DOTAP lipid film was hydrated in an aqueous
solution containing the water-soluble peptide. The unincorporated E7 peptides were not
removed from the liposome before they were injected into animals.
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Peptide encapsulation efficiency was determined by the percentage of the liposome-bound
peptide using LavaPep peptide quantification kit (Fluorotechnics, Sydney, Australia). Since
unincorporated lipopeptide aggregated and could not pass the exclusion filter, the incorporated
lipopeptide was measured as the amount associated with the extruded liposomes. The
liposomes were dissolved in 1% SDS, and the amount of peptide was measured as described
above. The data were reported as the mean ± SD (n = 3). For water-soluble peptides such as
native E7 and KSS-E7, the unbound peptide was separated from the complex by a Microcon
centrifugal filtration device (Millipore, Bedford, MA).9 The concentration of the unbound
peptide was measured using LavaPep according to the manufacturer's instructions. The
efficiency of encapsulation was determined as (100% – % unbound peptide) and was reported
as the mean ± SD (n = 3). The particle size and the ζ potential of the liposomal complexes were
measured following the manufacturer's instructions using a submicron particle sizer (NICOMP
particle sizing systems, Santa Barbra, CA) and a ZetaPlus (Brookhaven Instruments, Corp.,
Holtsville, NY), respectively.
Mice and Immunizations
All work performed on animals was in accordance with and approved by our institutional
IACUC. C57BL/6 female mice, 6–7 weeks old, were purchased from Charles River
Laboratories (Wilmington, MA) and were used in all animal studies. Subcutaneous (s.c.)
tumors were established by injecting TC-1 cells (105 cells) into the hair-trimmed flank of the
mouse on day 0. Mice were s.c. treated with a liposomal formulation comprising a constant
dose of DOTAP lipid 100 nmol and a varied amount of peptide at the other side of flank on
day 6 unless otherwise stated. The size of the tumor was measured using a caliper two or three
times a week. Tumor size was determined by multiplying the two largest dimensions of the
tumor.
Analysis of In Vivo CTL Response
In vivo CTL activity of E7-specific cytotoxic T cells was enumerated according to the protocol
of Byers et al.17 with minor modifications. In brief, spleen cells from syngenic mice were RBC
lysed followed by pulsing with 10 μM E7 peptide or without peptide in complete medium for
1 h at 37 °C. Both spleen cell populations were stained with equal amount of 2 μM PKH-26
(Sigma-Aldrich) according to the manufacturer's instructions. The peptide pulsed and unpulsed
populations were loaded with 4 and 0.4 μM CFSE (Molecular Probes), respectively, at 37 °C
for 15 min. The two cell populations were mixed together (1:1) for tail vein injection to the
control or the immunized mice (107 cells per mouse). At 16 h after injection, spleen cells from
the recipient mice were isolated, and single cell suspensions were prepared prior to flow
cytometric analysis. The number of CFSEhigh and CFSElow populations were determined, and
the in vivo E7 specific lysis percentage was enumerated according to a published equation.17
Intracellular Cytokine Staining
All antimouse antibodies used for flow cytometric analysis were purchased from BD
Pharmingen (San Diego, CA) or eBioscience, Inc. (San Diego, CA). For the measurement of
IFN-γ producing CD8+ T cells, spleen cells were isolated from the control or the immunized
mice 7–10 days after the last immunization. Spleen cells (2 × 106) were incubated with 5 μg/
mL of E7 peptide or without peptide for 6 h in the presence of 1 μL/mL of GolgiPlug (BD
Pharmingen). After being washed with FACS buffer, cells were stained directly with anti-CD8a
(53–6.7) on ice for 30 min. Prior to staining with anti-IFN-γ mAb (XMG1.2), cells were fixed
and permeabilized using the Cytofix/Cytoperm kit (BD Pharmingen) according to the
manufacturer's instructions. Cells were finally resuspended in 300 μL of stain buffer and
analyzed using a flow cytometer.
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MHC Class I Binding Assay
RMA-S cells at a concentration of 5 × 105 cells/mL were incubated overnight at 27 °C with
native E7 or KSS-E7 peptide (10 μM). Cells incubated with medium were used as a control.
Cells were then transferred to 37 °C and incubated for 2 h. After washes, cells were stained
with fluorescently conjugated mAbs against H-2Db or H-2Kb molecules on the cell surface
prior to flow cytometry analysis.
Statistical Analysis
Data were analyzed statistically using a one-way ANOVA and a two-tailed Student's t test.
Differences in data were considered statistically significant when the p value was less than
0.05.
Results
Encapsulation Efficiency of E7-Lipopeptide in the Cationic DOTAP Liposome
In order to improve the efficiency of the DOTAP/E7 therapeutic vaccine, one of the strategies
was to increase the incorporation of the antigen in the liposome by utilizing lipopeptides. The
lipopeptides used in this work are described in Table 1. The particle sizes of DOTAP/E7-
lipopeptide were not significantly changed compared to that of the DOTAP/E7, which was
102.6 ± 20.5 nm in diameter. Also, the ζ potential of DOTAP/E7-lipopeptide particles was
similar to that of DOTAP/E7 (44.5 ± 6.8 mV), indicating that the particle remains positively
charged after the water-soluble peptide is changed to a lipopeptide. However, significant
changes were found in the peptide entrapment efficiency in the liposome. When peptide loading
was 2.5 mol % of the total lipid, the entrapment efficiency of E7-lipopeptides (i.e., α- or ∊-PA-
KSS-E7) within DOTAP liposome reached up to 90% compared to ∼25% incorporation of the
water-soluble native E7 and KSS-E7 peptides. As shown in Figure 1, varying amounts of ∊-
PA-KSS-E7 lipopeptide (0.16 to 10 mol %) were dissolved with DOTAP lipid of 100 nmol in
an organic solvent, and the incorporation rate was measured following liposome preparation.
For all lipopeptide complexes, the entrapment efficiency decreased with increasing lipopeptide
loading. The incorporation rate was nearly 95% when lipopeptide concentration did not exceed
2.5 mol %. When the peptide loading was increased to 5 mol %, approximately 70–75%
entrapment efficiency was measured. Furthermore, less than 60% of lipopeptide was
incorporated into the liposomes when lipopeptide was loaded at 10 mol%. The loss of
lipopeptide at higher loading ratio could be mostly recovered from the polycarbonate
membrane which was used during extrusion (data not shown). These results demonstrate that
lipopeptides exhibit superior entrapment efficiency compared to the native E7 peptide.
However, the incorporation rate decreases with the increasing loading of lipopeptide; it
exceeded the solubility limit at the high loading ratios.
Antitumor Activity Was Enhanced by Incorporation of E7-Lipopeptide in the DOTAP
Liposome
Previous studies in our group have shown that a MHC class I peptide epitope derived from
HPV (type 16) E7 protein encapsulated in cationic DOTAP liposomes can generate a
therapeutic effect against the HPV16 E7 positive tumor cell line, TC-1.9,10 To test whether
the antitumor activity is enhanced by use of the lipopeptide, a series of E7-lipopeptides (Table
1) were synthesized and formulated in the DOTAP liposomes as described. As shown in Figure
2, TC-1 tumor-bearing mice were given a single-dose treatment on day 6 with DOTAP/E7
(containing 10 or 5 nmol of peptide) or DOTAP/E7-lipopeptide formulations containing 5 nmol
of the antigen. DOTAP/E7 with 5 nmol of peptide (suboptimal dose) did not show a significant
antitumor activity. On the contrary, both of the E7-lipopeptides (α- or ∊-PA-KSS-E7) at 5 nmol
of antigen, when formulated in DOTAP liposome, showed a significantly enhanced therapeutic
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effect (**p < 0.01) compared to the native E7 of 5 nmol. The antitumor activity elicited by the
lipopeptides was similar to that of DOTAP/E7 at 10 nmol (i.e., optimal peptide dose). DOTAP
liposome alone did not show antitumor activity. PA-E7, which is a palmitoylated E7 peptide
(without the KSS spacer), when formulated in DOTAP liposome failed to show an enhanced
antitumor activity as seen in other lipopeptide formulations, likely owing to the epitope being
hidden by directly attaching a fatty acid to the peptide. In addition, an unlipidated version of
KSS-elongated E7 peptide (KSS-E7) exhibited a larger effect (*p < 0.05) in tumor suppression
than the native E7. Under these conditions, E7-lipopeptides formulated in DOTAP liposome
showed an enhanced antitumor activity compared to the original DOTAP/E7 formulation.
In Vivo Cytotoxic T-Lymphocytes Were Elicited by DOTAP/E7-Lipopeptide Formulation
It is important to evaluate whether a candidate cancer vaccine would be suitable for inducing
a cytotoxic T-lymphocyte (CTL) response since the primary CTL is important for eradicating
the growth of tumor cells while the memory CTL is essential for preventing cancer recurrences.
18,19 To avoid the possible overestimation of CTL function due to in Vitro restimulation and
expansion process, we evaluated CTL induced in vivo by DOTAP/E7 or DOTAP/E7-
lipopeptide vaccine (Figure 3A). As described in the Materials and Methods, a mixture
containing equal amounts of E7-pulsed CFSEhigh and un-pulsed CFSElow spleen cells from a
syngenic donor was i.v. injected into mice at 7 days after the last immunization. The specific
lysis of E7-pulsed cells was analyzed by flow cytometry at 16 h after the adoptive transfer.
The mice immunized with DOTAP/E7 antigen (10 nmol) could generate a superior E7-specific
killing compared to those immunized with lower amounts of antigen DOTAP/E7 (5 nmol). In
contrast to the native E7 formulation, mice receiving 5 nmol of α- and ∊-PA-KSS-E7 but not
PA-E7 formulated in DOTAP liposome efficiently eliminated about 80% of E7-pulsed targets
(Figure 3B). In addition, the mice receiving DOTAP/KSS-E7, were also capable of killing 60%
of in vivo targets, while the mice receiving DOTAP alone did not generate a noticeable E7-
specific CTL response. The results suggested that E7-lipopeptides formulated in DOTAP
liposome elicited an improved in vivo CTL response in than the native E7 peptide.
IFN-γ Production from Functional CD8+ T Cells Was Induced by DOTAP/E7-Lipopeptide
To assess the epitope-specific immune response induced by DOTAP/E7-lipopeptide
vaccination, IFN-γ producing CD8+ T cells were analyzed (Figure 4). Spleen cells from control
or immunized mice were isolated at 1 week after the final immunization. After stimulation
with 5 μg/mL of E7 peptide (Figure 4A, bottom) or without peptide (Figure 4A, top),
intracellular staining for IFN-γ was performed. The numbers shown in the dot plots represent
the percentage of CD8 and IFN-γ double-positive cells within the CD8+ population. As
depicted in Figure 4B, the numbers of IFN-γ producing CD8+ cells were significantly higher
in mice that received 5 nmol of ∊-PA-KSS-E7 formulated in the DOTAP liposomes than those
of both 10 and 5 nmol of the native E7 formulation (**p < 0.01). Again, KSS-E7 showed a
superior result compared to the native E7 at the equal antigen amount. The IFN-γ production
by the CD8+ cells was in an E7-specific manner, as the unpulsed cells showed only background
level of the cytokine. These results show that incorporation of α- or ∊-PA-KSS-E7 lipopeptides
into DOTAP liposomes clearly enhanced the amount of IFN-γ producing CD8+ T lymphocytes
in the lymphoid organ.
H-2Db Was Up-Regulated by KSS-E7 Using RMA-S Binding Assay
Both native E7 and KSS-E7 are water-soluble peptides that reach similar entrapment efficiency
in liposome; KSS-E7 appears to have better immunogenicity compared to the native E7. To
elucidate the mechanism by which KSS-E7 peptide exhibited antigen activity superior to that
of the native E7, the binding of MHC class I molecules by E7 and KSS-E7 peptide was
investigated. E7 peptide (a.a. 49–57) is a known epitope restricted to H-2Db,20 and it up-
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regulated more than 4-fold of H-2Db molecules on RMA-S cells compared to the control
(Figure 5). Intriguingly, an 8-fold increase in the mean fluorescence was observed for KSS-
E7 peptide. No up-regulation of H-2Kb molecules was detected on RMA-S cells after
incubation with either E7 or KSS-E7 peptide. The results suggest that the KSS-E7 slowed down
the internalization of the MHC class I molecules. It is also possible that the KSS-E7 has an
improved binding affinity for H-2Db molecules, or an reduced degradation, than the native E7
peptide which may lead to an overall superior antitumor activity when formulated in the
DOTAP liposomes.
Potent Antitumor Activity Was Induced by DOTAP/E7-Lipopeptide Vaccine
To further study the potency of the DOTAP/E7-lipopeptide vaccine against the existing tumor,
the varied doses of ∊-PA-KSS-E7 (i.e., 1.25–10 nmol per injection) were investigated (Figure
6A). The tumor-bearing mice that received one single treatment of DOTAP/∊-PA-KSS-E7
with 5 or 10 nmol of antigen could induce full tumor growth inhibition (**p < 0.01) compared
to the partial tumor growth inhibition in those injected with DOTAP/E7 (5 nmol). The
formulation still showed a partial antitumor effect (*p < 0.05) when the lipopeptide amount
was decreased to as low as 1.25 nmol. To evaluate whether the improved vaccine could also
be effective in the treatment of TC-1 tumor of larger sizes, the treatment was delayed until day
10 instead of day 6 (Figure 6B). Whereas both DOTAP/E7 (10 nmol) and DOTAP/∊-PA-KSS-
E7 (5 nmol) vaccines given on day 6 showed an effective antitumor activity, mice receiving
the lipopeptide formulation on day 10 exhibited a superior effect on tumor inhibition than the
native E7 peptide given at the same day (*p < 0.05). Overall, the DOTAP/E7-lipopeptide
vaccine described in this work was capable of generating efficient antitumor activity even at
the low antigen dose compared to the original DOTAP/E7 formulation. Moreover, the
improved vaccine activity also demonstrated growth inhibition of larger tumors.
Discussion
Development of safe and effective therapeutic cancer vaccines for human use remains an urgent
and unmet medical need. In this report, we demonstrate an improved liposomal lipopeptide
vaccine for the treatment of HPV positive tumors. By linking to a monopalmitic acid to KSS-
elongated E7 peptide (at either α or ∊ position), the peptide encapsulation efficiency within
liposomes was higher than that of the unmodified E7 peptide. The DOTAP/E7-lipopeptide
vaccine induced an overall enhancement in generating antigen-specific CTL for eradicating
HPV positive TC-1 cells (Figure 3). When a reduced amount (5 nmol or less) of peptide dose
was given to the tumor-bearing mice, DOTAP/E7-lipopeptide exhibited a superior antitumor
activity compared to the original DOTAP/E7 formulation at a full dose (10 nmol) (Figures 2
and 6A). Furthermore, the therapeutic effect of DOTAP/E7-lipopeptide was also effective for
suppression of tumor growth in later stages of tumor progression, suggesting applications in
progressed cancer treatments (Figure 6B).
The enhanced antigenicity and antitumor activity of the lipopeptide were correlated with the
enhanced encapsulation of the lipopeptide in the liposomes. As shown in Table 1, the
entrapment efficiency of lipopeptide reached to 90% when the peptide loading is 2.5 mol%
among total lipid, whereas the native water soluble E7 peptide only incorporated into the
liposome at about 25%. Similar enhanced liposome encapsulation of lipopeptides has also been
reported.21-23 In order for the peptide to be presented by the MHC class I pathway, the peptide
has to enter the cytoplasm of the APC. Cationic liposomes deliver the encapsulated, but not
free, peptide into the APCs, allowing the peptide to be released and later presented in the MHC
class I pathway. Thus, the significantly higher the encapsulation of the peptide would allow
for increased peptide delivery and therefore, higher antigenicity, can be expected. However,
there is an exception to the rule.
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Our data indicate that the lipopeptide PA-E7 without the spacer sequence Lys-Ser-Ser achieved
of high degree of liposome encapsulation but did not show an enhanced antitumor activity
compared to those with the spacer amino acids. The phenomenon was likely a result of some
structural constraints where the conjugated fatty acid may cover the CTL epitope, thereby
minimizing its recognition. Verheul et al. have also shown that the amino acid spacer sequences
influence the immunological properties of the lipopeptide conjugates.24 In addition, to enter
the endosomal pathway as exogenous soluble protein and peptides, lipopeptides must be
processed to be free peptide again once entering into the cytoplasm of the APC. By adding a
linker sequences, it may prevent the CTL epitope from being altered during the processing of
the lipopeptide in the cytosol. Several additional spacer amino acids have been investigated
thus far including CSS and CSKKK,25,26 and they showed a stronger immunogenicity than
those without a spacer sequence.
The KSS-E7 peptide formulated in DOTAP appears to be a better vaccine formulation than
the native E7 peptide as demonstrated by the tumor growth inhibition and increased antigencity,
although their liposome encapsulation efficiencies were comparable. Interestingly, we found
that mice receiving DOTAP/KSS-E7 generated an increased functional CTL response (Figure
3 and 4) as well as an enhanced antitumor activity (Figure 2) compared with the native E7. It
is known that the capacity of a peptide to bind and stabilize MHC class I molecules is directly
correlated with its ability to induce specific CTL responses.20,27 Our results tempted us to
study the MHC class I binding affinity of the native and the KSS-elongated E7 peptides. RMA-
S cell line was originally selected from mutated cells on the basis of low cell surface expression
of MHC class I molecules and inability to present endogenous antigens. The synthesis of class
I molecule heavy and light chains is normal; however, the mutant cells undergoes various
protein degradation routes at 37 °C, resulting in a decreased number of MHC on the surface
of RMA-S cells. At 27 °C, the breakdown of MHC molecules is slow, and H-2Db or H-2Kb
molecules are able to appear on the cell surface at the reduced temperature.28 The labile class
I molecules at 37 °C can be stabilized by exposing cells to peptides which interact with
H-2Db or H-2Kb. Although the detailed mechanism is not known, our results shown in Figure
5 indicated that KSS-E7 bound with a higher affinity with H-2Db, but not H-2Kb, molecules
than the native E7 peptide. However, we cannot rule out the possibility that KSS-E7 may slow
down the internalization of the MHC class I molecules. Thus, the enhanced antigenicity of α-
and ∊-PA-KSS-E7 lipopeptides was likely due to both an enhanced liposome encapsulation
and an elevated biding affinity with the H-2Db molecule for antigen presentation.
In summary, the results from this report demonstrate that the improved formulation, DOTAP/
E7-lipopeptide, is a potential therapeutic vaccine for the treatment of HPV-positive tumors.
The vaccine described here maintains the benefits of simplicity and safety from its original
version, DOTAP/E7, which contains only two molecules, and the lipopeptide formulation
further improves the vaccine by reducing the amount of antigen required to suppress
progression of the cancer and tumor growth. Most importantly, the DOTAP/E7-lipopeptide
vaccine induced an overall increased CTL activity that is essential for the enhanced tumor
clearance and reduced rates of tumor recurrence. This novel formulation represents an excellent
candidate for future cancer vaccine development.
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DOTAP, 1,2-dioleoyl-3-trimethylammonium propane; APC, antigen presenting cells; LPD,
liposome-polycations-DNA.
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Entrapment efficiency of the E7-lipopeptide in DOTAP liposome. Lipopeptide varying from
0.16 to 10 nmol was mixed with DOTAP lipid of 100 nmol, and the peptide entrapment
efficiency was measured after liposome preparation. The solid line shows a regression curve
with a slope equal to 95%.
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Anti TC-1 tumor activity was enhanced by incorporation of E7-lipopeptide in the cationic
liposomal formulation. TC-1 tumor bearing mice (8–12 mice per group) received a single
treatment on day 6 with DOTAP/E7 (containing E7 peptide of 5 or 10 nmol) or DOTAP/E7-
lipopeptide (containing 5 nmol of peptide) or DOTAP lipid alone. Mice treated with dextrose
(5%) were used as a negative control. Tumor size was determined by multiplying the two largest
dimensions of the solid tumor. The mean of tumor sizes of each group at day 24 was compared
to that of the group which was received DOTAP/E7 (5 nmol) and was analyzed statistically
(*p < 0.05, **p < 0.01).
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Immunization with DOTAP/E7-lipopeptide formulation elicited an enhanced in vivo CTL
response. (A) C57BL/6 mice were s.c. immunized with DOTAP/E7 (containing E7 peptide of
5 or 10 nmol), DOTAP/KSS-E7 (5 nmol), DOTAP/E7-lipopeptide (5 nmol), or DOTAP lipid
alone at day 0 and day 10. Mice left untreated were used as a negative control. Seven days after
the last immunization, representative mice were i.v. injected with an equivalent amount of E7-
pulsed (labeled with 4 μM CFSE) and nonpulse (labeled with 0.4 μM CFSE) spleen cells
obtained from a syngenic donor. After 16 h, spleen cells from the adoptively transferred mice
were harvested, and the proportions of the CFSEhigh and CFSElow cells were analyzed by flow
cytometry. (B) Percentage of specific anti-E7 killing was shown. The mean of the percentage
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from each group was compared to that of the group received DOTAP/E7 (5 nmol) and was
analyzed statistically (**p < 0.01, n ) 4).
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Immunization with DOTAP/E7-lipopeptide increased the production of IFN-γ secreting
CD8+ T cells. (A) Mice were immunized as described, and 7 days after the last immunization,
spleen cells from immunized mice were isolated. The cells were stimulated in vitro with or
without E7 peptide (5 μg/mL) for 6 h and were stained with a surface CD8 marker and an
intracellular IFN-γ cytokine prior to FACS analysis. The numbers shown on contour plots
represent the percentages of CD8+IFN-γ+ T cells gated on the total CD8+ cells. Representative
figures in four experiments performed. (B) The percentage of CD8+IFN-γ+ double-positive
cells per 104 total CD8+ from each treatment group were shown as mean ± SD and were
statistically analyzed by paired t test (**p < 0.01, n = 4).
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MHC class I molecules up-regulation by E7 and KSS-E7 peptide. RMA-S cells were incubated
with E7 or KSS-E7 peptide at 10 μM, and the up-regulation of MHC class I molecules were
detected by a fluorescently conjugated mAb against H-2Db or H-2Kb. Cells treated with
medium were used as a control. The results are expressed as mean fluorescence intensity of
triplicate determination ± SD and were statistically analyzed by paired t test (**p < 0.01, n =
3).
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Potency of DOTAP/E7-lipopeptide vaccine for the treatment of TC-1 tumor. (A) Tumor
bearing mice were established as described and were given a single treatment of DOTAP/E7
or DOTAP/∊-PA-KSS-E7 formulation on day 6. Lipopeptides varying from 1.25 to 10 nmol
per dose were investigated. The mean of the tumor sizes from each group at day 24 was
compared to that of the group receiving DOTAP/E7 (5 nmol) and was analyzed by one-way
ANOVA (*p < 0.05, **p < 0.01, n = 6). (B) TC-1 tumor-bearing mice were treated with
DOTAP/E7 (10 nmol) or DOTAP/∊-PA-KSS-E7 (5 nmol) formulation on day 6 (solid
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symbols) or day 10 (open symbols). The mean of the tumor sizes at day 32 was compared
between the two formulations (*p < 0.05, n = 6).
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